Exagon Inc. has been acquired by Berger-Levrault Ltd.
The private shareholders of Exagon Inc. have sold the company to Berger-Levrault Ltd. for an undisclosed amount.
Exagon Inc. is a Quebec-based software design company that builds software that helps manage financial resources, human resources and investments for schools, corporations and government entities.
Berger Levrault Ltd., a creative and innovative France-based company, is the leading provider of business software in Europe. It has over 40,000 clients and generates revenues upwards of US$100 million annually.
Oaklins' team in Montreal advised the seller in this transaction.
Talk to the deal team
Related deals
Niscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Learn moreFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more